Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Spyre Therapeutics, Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Spyre Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Spyre Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Dec 2025 was $62,530,000, a 11% decline year-over-year.
  • Spyre Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 31 Dec 2025 was $155,218,000, a 25% increase year-over-year.
  • Spyre Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2025 was $155,218,000, a 25% increase from 2024.
  • Spyre Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $207,967,000, a 39% increase from 2023.
  • Spyre Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $338,816,000, a 304% decline from 2022.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Spyre Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $155,218,000 $62,530,000 -$6,235,000 -11% 01 Oct 2025 31 Dec 2025 10-K 19 Feb 2026 2025 FY
Q3 2025 $148,983,000 $11,183,000 +$57,827,000 +84% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $206,810,000 $36,717,000 +$2,120,000 +5.5% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $208,930,000 $44,788,000 -$963,000 -2.2% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $207,967,000 $56,295,000 +$6,885,000 +11% 01 Oct 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
Q3 2024 $214,852,000 $69,010,000 -$28,906,000 -72% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $185,946,000 $38,837,000 +$178,237,000 +82% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $364,183,000 $43,825,000 -$25,367,000 -137% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $338,816,000 $63,180,000 -$44,422,000 -237% 01 Oct 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
Q3 2023 $294,394,000 $40,104,000 -$21,661,000 -117% 01 Jul 2023 30 Sep 2023 10-Q/A 18 Nov 2024 2024 Q3
Q2 2023 $272,733,000 $217,074,000 -$194,760,000 -873% 01 Apr 2023 30 Jun 2023 10-Q/A 18 Nov 2024 2024 Q2
Q1 2023 $77,973,000 $18,458,000 +$5,978,000 +24% 01 Jan 2023 31 Mar 2023 10-Q/A 18 Nov 2024 2024 Q1
Q4 2022 $83,951,000 $18,758,000 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $18,443,000 +$1,838,000 +9.1% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $22,314,000 -$15,576,000 -231% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $24,436,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $20,281,000 -$2,248,000 -12% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $6,738,000 +$14,680,000 +69% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q3 2020 $18,033,000 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $21,418,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2

Spyre Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $155,218,000 +$52,749,000 +25% 01 Jan 2025 31 Dec 2025 10-K 19 Feb 2026 2025 FY
2024 $207,967,000 +$130,849,000 +39% 01 Jan 2024 31 Dec 2024 10-K 19 Feb 2026 2025 FY
2023 $338,816,000 -$254,865,000 -304% 01 Jan 2023 31 Dec 2023 10-K 19 Feb 2026 2025 FY
2022 $83,951,000 -$18,291,000 -28% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $65,660,000 +$15,233,000 +19% 01 Jan 2021 31 Dec 2021 10-K/A 18 Nov 2024 2023 FY
2020 $80,893,000 -$2,639,000 -3.4% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $78,254,000 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.